Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Life expectancy greater than or equal to (\>/=) 12 weeks
Availability and willingness to provide sufficient tumor tissue sample for testing
Dose-escalation stage: Participants with histologically documented incurable, locally advanced, or metastatic epithelial malignancy that has progressed despite standard therapy or for which no standard therapy exists
Expansion stage: Participants with one of the following epithelial, histologically-documented, incurable, locally advanced, or metastatic tumor that has progressed despite standard therapy or for which no standard therapy exists: CRC, NSCLC, HNSCC, or pancreatic cancer
Use of an effective means of contraception (e.g., abstinence, hormonal or double barrier method, surgically sterilized partner) for men and women of childbearing potential while enrolled in the study
You may not be if
Less than (\<) 4 weeks since the last anti-tumor therapy prior to Day 1 of study treatment
Major surgical procedure within 4 weeks prior to Cycle 1, Day 1
Leptomeningeal disease as the only manifestation of the current malignancy
Active infection requiring IV antibiotics
Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Current severe, uncontrolled systemic disease
History of cardiac heart failure of any New York Heart Association criteria or serious cardiac arrhythmia requiring treatment
History of myocardial infarction within 6 months before Cycle 1, Day 1, or history of unstable angina
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
History of interstitial lung disease
History of severe allergic or hypersensitivity reaction to other therapeutic antibodies that required discontinuation of therapy
Known human immunodeficiency virus (HIV) infection
Primary central nervous system (CNS) malignancy or untreated/active CNS metastases
Significant traumatic injury within 4 weeks before Cycle 1, Day 1
Pregnancy or lactation
Clareo Health | A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
